MDS Reports Second Quarter 2009 Financi...(o deliver positive EBITDA from steriliza...),Health

MDS continues to work to secure a long-term reliable supply of medical isotopes. In 1996, MDS Nordion contracted with AECL to complete and commission the MAPLE reactors, which were intended to replace the NRU. In May 2008, this project was unilaterally discontinued by AECL and the Government of Canada. MDS invested over $350 million in the MAPLE project, and believes that the completion of the MAPLE reactors is the best solution to provide global medical isotope supply. More recently, MDS Nordion urged the AECL and Canadian Government to consult with international experts and obtain their assistance to activating the MAPLE project to address the current medical-isotope supply shortage. In addition, MDS Nordion is examining longer-term supply alternatives and announced in the second quarter its collaboration with TRIUMF, Canada's national laboratory for particle and nuclear physics, to study the feasibility of producing a viable and reliable supply of photo fission-based Molybdenum-99.

    MDS Analytical Technologies

                                                                    % Change
    (millions of U.S. dollars)             Q2 2009      Q2 2008     Reported
    -------------------------------------------------------------------------
    Net revenue                            $    87      $   118         (26%)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Adjusted EBITDA                        $    13      $    17         (24%)
                                               15%          14%
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

In the second quarter, MDS Analyt
'/>"/>